<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="970">
  <stage>Registered</stage>
  <submitdate>1/11/2005</submitdate>
  <approvaldate>1/11/2005</approvaldate>
  <nctid>NCT00252798</nctid>
  <trial_identification>
    <studytitle>ZD1839 (Iressa) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer</studytitle>
    <scientifictitle>A Phase I Trial to Evaluate ZD1839(Iressa) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>1839IL/0073</secondaryid>
    <secondaryid>D7913C00073</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non Small Cell Lung Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Gefitinib
Treatment: drugs - Carboplatin
Treatment: drugs - Paclitaxel
Treatment: surgery - Radiation

Treatment: drugs: Gefitinib


Treatment: drugs: Carboplatin


Treatment: drugs: Paclitaxel


Treatment: surgery: Radiation


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the Maximum tolerated dose, if any, of the combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up to 45 mg/m2 paclitaxel.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the activity potential of the combination of ZD1839, carboplatin, paclitaxel &amp; radiation therapy</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Estimating the objective response rate (complete response [CR] &amp; partial response [PR]) as assessed by positron emission tomography with (18F)-labelled fluorodeoxyglucose (PET-FDG)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate the objective response rate (CR and PR) as assessed by computerised tomography (CT) scan</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate the complete response rate (CR) as assessed by PET-FDG</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate progression free survival (PFS) as assessed by clinical examination, chest x-ray, CT scan Â± PET-FDG</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate overall survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To characterise the safety and tolerability of ZD1839 combined with concurrent carboplatin, paclitaxel and radiation</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the site of first failure (characterised as local-regional, distant or both)</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients with histologically or cytologically confirmed locally advanced stage IIIA or
             IIIB NSCLC (without pleural effusion)

          -  Patients with apical tumours and supraclavicular nodes are acceptable if both can be
             easily encompassed in one radiation field

          -  Minimum life expectancy with treatment of 6 months

          -  WHO performance status 0-1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with previous malignancies other than NSCLC

          -  Previous radiotherapy for NSCLC

          -  Previous immunotherapy or chemotherapy

          -  Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer
             therapy

          -  Forced expiratory volume in 1 second (FEV1) less than 1 litre (L)

          -  Absolute neutrophil count (ANC) less than 1.5 x 109/L or platelets less than 100 x
             109/L

          -  Serum bilirubin greater than 1.25 times the upper limit of reference range

          -  ALT or AST greater than 2.5 times the ULRR</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Research Site - Woolloonabba</hospital>
    <hospital>Research Site - East Melbourne</hospital>
    <postcode> - Woolloonabba</postcode>
    <postcode> - East Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of the trial is to determine the Maximum tolerated dose, if any, of the
      combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up
      to 45 mg/m2 paclitaxel.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00252798</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>AstraZeneca Australia Medical Director, MD</name>
      <address>AstraZeneca</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>